<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770651</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01-030</org_study_id>
    <secondary_id>APPOSITION-AMI II</secondary_id>
    <nct_id>NCT02770651</nct_id>
  </id_info>
  <brief_title>Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI</brief_title>
  <official_title>LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the incidence of late incomplete stent apposition
      (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting
      stent (EES) with bioabsorbable polymer (SYNERGY™, Boston Scientific,Nattick, MA, USA) versus
      zotarolimus-eluting stent (ZES) with permanent polymer(Resolute Onyx™, Medtronic, Santa Rosa,
      CA, USA) implantation in patients with AMI at 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been known that persistence of polymer may affect the late/very late safety and
      efficacy of drug eluting stent (DES) although polymer provides a reservoir for programmed
      drug release. Newer durable polymers may have enhanced biocompatibility and seem to be
      associated with improved clinical outcomes. However, they have still been incriminated in the
      occurrence of inflammation, neo-atherosclerosis, and thrombosis. Therefore, the investigators
      will evaluate the vascular tissue reaction after different kinds of DES implantation under
      the high thrombogenic circumstance of acute myocardial infarction (AMI).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of malapposed and uncovered stent strut at 12±1 months in both DES groups</measure>
    <time_frame>12month</time_frame>
    <description>Incidence of malapposed and uncovered stent strut measured by OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent neointima cross-sectional area</measure>
    <time_frame>12month</time_frame>
    <description>By OCT, percentage neointima cross sectional area can be obtained by dividing the neointimal area by the stent area.(neointima cross-sectional area in mm²(Quadratmillimeter)/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean neointima thickness</measure>
    <time_frame>12month</time_frame>
    <description>By OCT, neointima thickness can be measured as distance from the endoluminal surface of the neointima to the stent strut.(mean neointima thickness in millimeter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphologic characteristics of neointima</measure>
    <time_frame>12month</time_frame>
    <description>Morphologic characteristics of neointima measured by OCT(morphologic characteristics of neointima is one of fibrous, fibrocalcific, lipid-laden)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Optical Coherence Tomography</arm_group_label>
    <description>To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-Eluting stent</intervention_name>
    <description>Everolimus-Eluting stent with bioabsorbable polymer</description>
    <arm_group_label>Optical Coherence Tomography</arm_group_label>
    <other_name>Synergy™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-Eluting stent</intervention_name>
    <description>Zotarolimus-Eluting stent with permanent polymer</description>
    <arm_group_label>Optical Coherence Tomography</arm_group_label>
    <other_name>Resolute Onyx™</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute myocardial infarction including ST-segment elevation myocardial infarction (STEMI) or
        non ST-segment elevation myocardial infarction (NSTEMI) treated with PCI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction including ST-segment elevation myocardial infarction
             (STEMI) or non ST-segment elevation myocardial infarction (NSTEMI) treated with PCI

          -  Patient ≥ 18 years of age

          -  Patient judged suitable to receive anti-platelet drugs of ASA and ticagrelor for at
             least 12 months after the procedure

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic, OCT follow up and provides informed consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

          -  culprit lesion

        Exclusion Criteria:

          -  The patient has a known hypersensitivity or contraindication to any of the following
             medications: heparin, abciximab, aspirin, ticagrelor, everolimus, zotarolimus,
             polymer, platinum chromium, cobalt chromium, contrast media

          -  Female of childbearing potential unless a pregnancy test is negative or who possibly
             plan to become pregnant any time after enrollment

          -  Cardiogenic shock

          -  Patient with left ventricular ejection fraction &lt;30%

          -  Patient with left main disease

          -  Patient with In-stent restenosis (ISR) at target vessel (either bare metal stent or
             DES, non-target vessel ISR is permitted)

          -  Patient with impaired renal function (creatinine &gt;2.0mg/dL)

          -  Patient with inadequate OCT images quality due to severe calcification, vessel
             tortuosity and artifacts

          -  bifucation lesion needs complex procedure with insert two or more Drug eluting stents.

          -  lesion length &gt;30mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Ho Hur, Postdoctoral</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Qian J, Zhang YJ, Xu B, Yang YJ, Yan HB, Sun ZW, Zhao YL, Tang YD, Gao Z, Chen J, Cui JG, Mintz GS, Gao RL. Optical coherence tomography assessment of a PLGA-polymer with electro-grafting base layer versus a PLA-polymer sirolimus-eluting stent at three-month follow-up: the BuMA-OCT randomised trial. EuroIntervention. 2014 Nov;10(7):806-14. doi: 10.4244/EIJY14M07_17.</citation>
    <PMID>25033105</PMID>
  </reference>
  <reference>
    <citation>Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012 Jan 24;125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022. Epub 2011 Dec 16.</citation>
    <PMID>22179532</PMID>
  </reference>
  <reference>
    <citation>Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Cho YK, Nam CW, Hur SH, Jang Y, Hong MK. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013 Jan 1;111(1):1-5. doi: 10.1016/j.amjcard.2012.08.037. Epub 2012 Oct 2. Erratum in: Am J Cardiol. 2013 Sep 1;112(5):746.</citation>
    <PMID>23040589</PMID>
  </reference>
  <reference>
    <citation>Karjalainen PP, Varho V, Nammas W, Mikkelsson J, Pietilä M, Ylitalo A, Airaksinen JK, Sia J, Nyman K, Biancari F, Kiviniemi T. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome –HATTRICK-OCT trial. Circ J. 2015;79(2):360-7. doi: 10.1253/circj.CJ-14-1000. Epub 2014 Dec 15.</citation>
    <PMID>25502167</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Ho Hur</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>optical coherence tomography</keyword>
  <keyword>everolimus-eluting stent</keyword>
  <keyword>zotarolimus-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

